JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 146.9 USD | +1.09% |
|
-0.07% | -6.30% |
| 06-02 | GSK blood cancer drug nearly halves risk of death in late-stage trial | RE |
| 06-01 | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
Presenter SpeechMichael Weinstein (Analysts)Good afternoon, everybody, and welcome to the afte...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
12/06/2024
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
146.7
USD
Average target price
171.9
USD
Spread / Average Target
+17.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.30% | 353B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Transcript : Johnson & Johnson Presents at JPMorgan 34th Annual Healthcare Conference, Jan-11-2016 02
